TABLE IV.
Results of Fitting Proportional Hazards Model to OS and EFS
| OS
|
EFS
|
|||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
| G-CSF | 1 | – | – | 1 | – | – |
| Cy+G-CSF | 0.94 | (0.55, 1.62) | 0.83 | 1.11 | (0.64, 1.92) | 0.72 |
| Age | 1.01 | (0.98, 1.04) | 0.60 | 1.01 | (0.98, 1.04) | 0.54 |
| ISS Stage | ||||||
| I or II | 1 | – | – | 1 | – | – |
| III | 2.03 | (1.04, 3.95) | 0.04 | 2.51 | (1.28, 4.93) | 0.01 |
| Bortezomib with induction | ||||||
| no | 1 | – | – | 1 | – | – |
| yes | 0.92 | (0.49, 1.74) | 0.80 | 0.88 | (0.46, 1.68) | 0.71 |
| Lenalidomide or thalidomide with induction | ||||||
| no | 1 | – | – | 1 | – | – |
| yes | 1.16 | (0.67, 2.03) | 0.59 | 1.25 | (0.71, 2.19) | 0.44 |
| Pre-ASCT VGPR or better | ||||||
| no | 1 | – | – | 1 | – | – |
| yes | 0.53 | (0.29, 0.96) | 0.04 | 0.40 | (0.21, 0.74) | 0.00 |
| Full-dose melphalan conditioning | ||||||
| no | 1 | – | – | 1 | – | – |
| yes | 1.18 | (0.52, 2.67) | 0.69 | 1.43 | (0.63, 3.23) | 0.39 |
| Bone marrow cytogenetics/FISH | ||||||
| normal | 1 | – | – | 1 | – | – |
| abnormal | 0.89 | (0.47, 1.69) | 0.72 | 0.75 | (0.40, 1.41) | 0.37 |
| Year of ASCT | ||||||
| 2001–2003 | 1 | – | – | 1 | – | – |
| 2004–2006 | 0.58 | (0.26, 1.25) | 0.16 | 0.78 | (0.36, 1.67) | 0.52 |
| 2007–2008 | 0.70 | (0.31, 1.58) | 0.38 | 0.67 | (0.30, 1.53) | 0.35 |
ASCT = high-dose chemotherapy with autologous stem cell transplantation; VGPR = very good partial response; ISS = International staging system; CI = confidence interval; FISH = fluorescent in situ hybridization; OS = overall survival; EFS = event-free survival.